C
Casey Kopczynski
Researcher at Durham University
Publications - 69
Citations - 2224
Casey Kopczynski is an academic researcher from Durham University. The author has contributed to research in topics: Ocular hypertension & Intraocular pressure. The author has an hindex of 22, co-authored 64 publications receiving 1637 citations. Previous affiliations of Casey Kopczynski include Research Triangle Park.
Papers
More filters
Journal ArticleDOI
Consensus recommendations for trabecular meshwork cell isolation, characterization and culture
Kate E. Keller,Sanjoy K. Bhattacharya,Theresa Borrás,Thomas M. Brunner,Sunee Chansangpetch,Abbott F. Clark,W. Michael Dismuke,Yiqin Du,Michael H. Elliott,C. Ross Ethier,Jennifer A. Faralli,Thomas F. Freddo,Rudolf Fuchshofer,Michael Giovingo,Haiyan Gong,Pedro Gonzalez,Alex S. Huang,Murray A. Johnstone,Paul L. Kaufman,Mary J. Kelley,Paul A. Knepper,Casey Kopczynski,John Kuchtey,Rachel W. Kuchtey,Markus H. Kuehn,Raquel L. Lieberman,Shan C. Lin,Paloma B. Liton,Yutao Liu,Elke Lütjen-Drecoll,Weiming Mao,Marisse Masis-Solano,Fiona McDonnell,Colleen M McDowell,Darryl R. Overby,Padmanabhan P. Pattabiraman,Vijay Krishna Raghunathan,P. Vasanth Rao,Douglas J Rhee,Uttio Roy Chowdhury,Paul Russell,John R. Samples,Donald Schwartz,Evan B. Stubbs,Ernst R. Tamm,James C. Tan,Carol B. Toris,Karen Y. Torrejon,Janice A. Vranka,Mary K. Wirtz,Thomas Yorio,Jie Zhang,Gulab Zode,Michael P. Fautsch,Donna M. Peters,Ted S. Acott,W. Daniel Stamer +56 more
TL;DR: Having a set of standard practices for TM cells will increase the scientific rigor when used as a model, and enable other researchers to replicate and build upon previous findings.
Journal ArticleDOI
Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
Janet B. Serle,L. Jay Katz,Eugene B McLaurin,Theresa Heah,Nancy Ramirez-Davis,Dale W. Usner,Gary D. Novack,Gary D. Novack,Casey Kopczynski,Rocket Study Groups +9 more
TL;DR: Once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma and the novel pharmacology and aqueous humor dynamic effects of this molecule suggest it may be a useful addition to the armamentarium of ocular hypotensive medications.
Journal ArticleDOI
Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Cheng-Wen Lin,Bryan Sherman,Lori Moore,Carmen L. Laethem,Da-Wen Lu,Padmanabhan P. Pattabiraman,Ponugoti Vasantha Rao,Mitchell A. Delong,Casey Kopczynski +8 more
TL;DR: Netarsudil is a novel ROCK/NET inhibitor with high potency in biochemical and cell-based assays, an ability to produce large and durable IOP reductions in animal models, and favorable pharmacokinetic and ocular tolerability profiles.
Journal ArticleDOI
Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
TL;DR: AR-12286 was well tolerated and provided clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma.
Journal ArticleDOI
Aqueous humor outflow: what do we know? Where will it lead us?
Michael P. Fautsch,Douglas H. Johnson,Ted S. Acott,Makoto Aihara,Sanjoy K. Bhattacharya,Terete Borras,Carl B. Camras,Mortimer M. Civan,Abbot F. Clark,Craig E. Crosson,Jonathan G Crowston,David L. Epstein,C. Ross Ethier,Thomas F. Freddo,Haiyan Gong,Pedro Gonzalez,Simon W. M. John,Mark Johnson,Paul L. Kaufman,Paul A. Knepper,James D. Lindsey,Elke Lütjen-Drecoll,Donna M. Peters,P. Vasantha Rao,Sayon Roy,Paul Russell,Daniel Stamer,Ernst R. Tamm,Carol B. Toris,Robert N. Weinreb,Beatrice Y.J.T. Yue,Paul Bornstein,Peter F. Davies,Benjamin Geiger,Dontscho Kerjaschki,James B. Mitchell,Eveline E. Schneeberger,Alan W. Stitt,David C. Zawieja,C. Bosworth,John W. Grunden,Elizabeth E. Kim,Casey Kopczynski,Achim H.-P. Krauss,Noorjahan Panjwani,Christopher A. Paterson,G. Prasanna,Douglas J. Rhee,Andy Whitlock,Darrell WuDunn +49 more
TL;DR: This conference summary highlights the ideas discussed and introduces areas that need further exploration of the aqueous humor outflow pathway.